Medicare Enrolled
Dr. Melissa King, M.D.
Hematology & Oncology · Eglin Afb, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. King from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. King?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. King
Dr. Melissa King is a hematology & oncology specialist in Eglin Afb, FL, with 18 years of NPI registration. Based on federal Medicare data, Dr. King performed 38,173 Medicare services across 1,516 unique beneficiaries.
Between the years covered by Open Payments, Dr. King received a total of $11,086 from 77 pharmaceutical and/or device companies across 598 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. King is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 19% volume in FL
$11,086 industry payments
Medicare Practice Summary
Medicare Utilization ↗38,173
Medicare services
Top 19% in FL for hematology & oncology
1,516
Unique beneficiaries
$29
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,121 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 15,800 | $43 | $71 |
| Denosumab injection (Prolia/Xgeva) | 11,160 | $19 | $37 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,544 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,680 | $1 | $8 |
| Cetirizine hydrochloride injection, 0.5 mg An injection containing 0.5 mg of cetirizine hydrochloride, an antihistamine medication. |
1,620 | $12 | $20 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,137 | $8 | $17 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
531 | $8 | $11 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
425 | $64 | $125 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
389 | $98 | $230 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
387 | $91 | $184 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
344 | $16 | $32 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
334 | $22 | $58 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
307 | $12 | $37 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
252 | $10 | $30 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
170 | $133 | $258 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
147 | $52 | $104 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
133 | $22 | $53 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
122 | $48 | $115 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
108 | $42 | $102 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
85 | $15 | $31 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
84 | $130 | $346 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
78 | $1 | $3 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
65 | $48 | $103 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
48 | $24 | $83 |
| New patient office visit, complex (60-74 min) | 46 | $158 | $321 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
39 | $63 | $115 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
37 | $18 | $38 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
35 | $1 | $4 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
24 | $114 | $237 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
23 | $137 | $250 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
19 | $79 | $160 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
2.8% high complexity
88.8% medium
8.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$11,086
Total received (2018-2024)
Avg $1,584/year across 7 years
Top 34% in FL for hematology & oncology
77
Companies
598
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,996 (99.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$90 (0.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,426
2023
$4,103
2022
$1,924
2021
$15
2020
$132
2019
$134
2018
$352
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$727
Celgene Corporation
$723
PFIZER INC.
$629
Janssen Biotech, Inc.
$622
Merck Sharp & Dohme LLC
$524
GENZYME CORPORATION
$467
Amgen Inc.
$456
AstraZeneca Pharmaceuticals LP
$431
E.R. Squibb & Sons, L.L.C.
$430
Regeneron Healthcare Solutions, Inc.
$418
Genentech USA, Inc.
$358
Lilly USA, LLC
$317
Daiichi Sankyo Inc.
$290
JAZZ PHARMACEUTICALS INC.
$236
Seagen Inc.
$206
Exelixis Inc.
$188
Stemline Therapeutics Inc.
$185
Astellas Pharma US Inc
$182
Takeda Pharmaceuticals U.S.A., Inc.
$173
Blueprint Medicines Corporation
$171
PharmaEssentia USA Corporation
$143
Merck Sharp & Dohme Corporation
$140
ARRAY BIOPHARMA INC
$140
Coherus Biosciences Inc.
$138
GlaxoSmithKline, LLC.
$137
Mission Pharmacal Company
$135
ABBVIE INC.
$133
Alexion Pharmaceuticals, Inc.
$131
Spectrum Pharmaceuticals Inc.
$129
RECORDATI_RARE_DISEASES_INC.
$116
Deciphera Pharmaceuticals Inc.
$109
EMD Serono, Inc.
$108
Bayer Healthcare Pharmaceuticals Inc.
$108
Mirati Therapeutics, Inc.
$106
Eisai Inc.
$104
Sumitomo Pharma America, Inc.
$103
Gilead Sciences, Inc.
$101
Incyte Corporation
$96
SOBI, INC
$78
TerSera Therapeutics LLC
$74
SANOFI-AVENTIS U.S. LLC
$70
Ipsen Biopharmaceuticals, Inc
$63
Heron Therapeutics, Inc.
$60
Sobi, Inc
$52
Pharmacosmos Therapeutics Inc.
$50
Karyopharm Therapeutics Inc.
$49
Adaptive Biotechnologies Corporation
$46
AVEO Pharmaceuticals, Inc.
$45
Boehringer Ingelheim Pharmaceuticals, Inc.
$44
Genmab U.S., Inc.
$40
Ortho Dermatologics, a division of Bausch Health US, LLC
$33
SUN PHARMACEUTICAL INDUSTRIES INC.
$30
Janssen Scientific Affairs, LLC
$30
EISAI INC.
$28
BeiGene USA, Inc.
$27
Pharming Healthcare, Inc.
$23
SpringWorks Therapeutics, Inc.
$22
Aveo Pharmaceuticals, Inc.
$21
Progenics Pharmaceuticals, Inc.
$20
ADC Therapeutics America, Inc.
$19
Paratek Pharmaceuticals, Inc.
$19
Iovance Biotherapeutics, Inc.
$18
CSL Behring
$17
Taiho Oncology, Inc.
$17
MorphoSys, US Inc.
$17
G1 Therapeutics, Inc.
$16
Amneal Pharmaceuticals LLC
$16
Verity Pharmaceuticals Inc.
$15
Sun Pharmaceutical Industries Inc.
$15
ImmunoGen, Inc.
$14
Acrotech Biopharma Inc.
$14
Sunovion Pharmaceuticals Inc.
$14
Bayer HealthCare Pharmaceuticals Inc.
$13
Rigel Pharmaceuticals, Inc.
$12
Myovant Sciences Inc.
$12
EUSA Pharma (US) LLC
$12
PUMA BIOTECHNOLOGY, INC.
$12
Top 3 companies account for 18.8% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALPROLIX · ALUNBRIG · AVASTIN · AYVAKIT · Alecensa · Amtagvi · Avar · BELEODAQ · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CINVANTI · COSELA · CYRAMZA · Columvi · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELITEK · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · EVENITY · Enhertu · Epkinly · FOTIVDA · Fabhalta · GAZYVA · GILOTRIF · HYMPAVZI · Hizentra · IBRANCE · ICLUSIG · ILUMYA (tildrakizumab-asmn) injection · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LOQTORZI · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · NUZYRA · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Odomzo · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PYLARIFY · Padcev · Phesgo · Polivy · Pomalyst · QINLOCK · Quzyttir · REBLOZYL · RETEVMO · ROLVEDON · RUCONEST · RYBREVANT · Repatha · Rezlidhia · SARCLISA · SCEMBLIX · SILIQ · SOMATULINE DEPOT · SYLVANT · Somatuline Depot · Stivarga · Sylvant · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tecentriq · Trelstar · Trodelvy · ULTOMIRIS · UTIBRON · Udenyca · VENCLEXTA · VERZENIO · VPRIV · Venclexta · XALKORI · XPOVIO · XTANDI · Xospata · Xtandi · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $29 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
8
Per 100K population
3.7
County median income
$79,097
Nearest hospital
96th Medical Group (Eglin AFB)
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. King is a mixed practice specialist, with above-average Medicare volume (top 19% in FL), with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. King experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. King performed 15,800 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. King receive payments from pharmaceutical companies?
Yes. Dr. King received a total of $11,086 from 77 companies across 598 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. King's costs compare to other hematology & oncology specialists in Eglin Afb?
Dr. King's average Medicare payment per service is $29. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. King) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Eglin Afb
Browse hematology & oncology specialists in Eglin Afb ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in FL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in FL
Which FL hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology